Letter to the Editor: Host Response to SARS COV-2 and its Effect

Rahman Sabrina,Anik Md Evangel Islam,Hossain Mohammad Nabil,Sarwar Asm,Razzak Khandaker Sabit Bin,Rahman Md Moshiur,Bushra Anika

doi:10.36959/577/494

Abstract

SARS COV-2 is an airborne disease. Clinical and lab appearances incorporate fever, chills, myalgia, running nose, dyspnoea, pneumonia, lymphopenia, neutrophilia, thrombocytopenia, and raised serum lactate dehydrogenase, alanine aminotransferase, and creatine kinase. Medical service providers are at the highest risk and the aged people with multiple comorbid diseases are also vulnerable.

Highlights

Sabrina Rahman1, Md Moshiur Rahman2*, ASM Sarwar3, Khandaker Sabit Bin Razzak4, Anika Bushra5, Mohammad Nabil Hossain6 and Md Evangel Islam Anik7
Data from other free examinations show that SARS-express T lymphocytes against S, M, E, and N proteins are recognized in recovering SARS tests from one to four years post-infection using covering peptides against singular fundamental proteins, rather than a genome-wide system [1]
Memory T cells express to SARS-CoV further declined and could be perceived in a little degree of picking up quality patients [2]

Summary

Introduction

Sabrina Rahman1, Md Moshiur Rahman2*, ASM Sarwar3, Khandaker Sabit Bin Razzak4, Anika Bushra5, Mohammad Nabil Hossain6 and Md Evangel Islam Anik7. Medical service providers are at the highest risk and the aged people with multiple comorbid diseases are vulnerable. The treatment has been exact, and there is no authorized SARS COV-2 vaccine for people up until now. Notwithstanding, the nearness of enduring killing antibodies and memory T-and B-lymphocytes in improving SARS patients raises trust in dynamic inoculation.

Results

Conclusion